A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Immuneering Corporation
Immuneering Corporation
Immuneering Corporation
Pfizer
AO GENERIUM
Adaptimmune
Karyopharm Therapeutics Inc
Santa Maria Biotherapeutics
Novartis
Celldex Therapeutics
Merck Sharp & Dohme LLC
Bristol-Myers Squibb